KR102754522B1 - 아데노신 수용체 길항제 및 이의 용도 - Google Patents
아데노신 수용체 길항제 및 이의 용도 Download PDFInfo
- Publication number
- KR102754522B1 KR102754522B1 KR1020207028522A KR20207028522A KR102754522B1 KR 102754522 B1 KR102754522 B1 KR 102754522B1 KR 1020207028522 A KR1020207028522 A KR 1020207028522A KR 20207028522 A KR20207028522 A KR 20207028522A KR 102754522 B1 KR102754522 B1 KR 102754522B1
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- unsubstituted
- compound
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638737P | 2018-03-05 | 2018-03-05 | |
| US62/638,737 | 2018-03-05 | ||
| US201862688088P | 2018-06-21 | 2018-06-21 | |
| US62/688,088 | 2018-06-21 | ||
| PCT/US2019/020810 WO2019173380A1 (en) | 2018-03-05 | 2019-03-05 | Adenosine receptor antagonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200132901A KR20200132901A (ko) | 2020-11-25 |
| KR102754522B1 true KR102754522B1 (ko) | 2025-01-13 |
Family
ID=67847428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207028522A Active KR102754522B1 (ko) | 2018-03-05 | 2019-03-05 | 아데노신 수용체 길항제 및 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210040097A1 (https=) |
| EP (2) | EP3762386B1 (https=) |
| JP (2) | JP7849948B2 (https=) |
| KR (1) | KR102754522B1 (https=) |
| CN (1) | CN112218867B (https=) |
| AU (2) | AU2019232736B2 (https=) |
| BR (1) | BR112020018158A2 (https=) |
| ES (1) | ES2975753T3 (https=) |
| IL (1) | IL277144B2 (https=) |
| MX (1) | MX2020009286A (https=) |
| SG (1) | SG11202008611UA (https=) |
| WO (1) | WO2019173380A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2975753T3 (es) | 2018-03-05 | 2024-07-12 | Teon Therapeutics Inc | Antagonistas del receptor de adenosina y usos de los mismos |
| WO2022032091A1 (en) * | 2020-08-07 | 2022-02-10 | Teon Therapeutics, Inc. | Combination therapy with adenosine receptor antagonists |
| CN116322698A (zh) * | 2020-09-04 | 2023-06-23 | 泰昂治疗公司 | 腺苷a2b受体拮抗剂的共晶 |
| WO2022256550A1 (en) | 2021-06-04 | 2022-12-08 | Teon Therapeutics, Inc. | Crystalline forms of an adenosine a2b receptor antagonist |
| TW202327612A (zh) * | 2021-09-10 | 2023-07-16 | 美商天恩治療有限公司 | 使用腺苷受體拮抗劑之改良療法 |
| EP4554943A1 (en) * | 2022-07-14 | 2025-05-21 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| WO2026035860A1 (en) | 2024-08-07 | 2026-02-12 | Teon Therapeutics, Inc. | Formulations of adenosine receptor antagonist |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466811A (en) * | 1994-07-18 | 1995-11-14 | Merck & Co., Inc. | Dioxolenylmethyl carbamates pro moieties for amine drugs |
| CA2323047C (en) * | 1998-04-15 | 2005-03-15 | Warner-Lambert Company | Prodrugs of benzofuranylmethyl carbamate nk, antagonists |
| US20080318983A1 (en) | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7125993B2 (en) | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| DK1444233T3 (da) * | 2001-11-09 | 2011-10-17 | Gilead Palo Alto Inc | A2B-adenosinreceptorantagonister |
| HRP20040853A2 (en) * | 2002-03-20 | 2004-12-31 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| DE60322748D1 (de) * | 2003-05-06 | 2008-09-18 | Cv Therapeutics Inc | Xanthinderivate als a2b-adenosinrezeptorantagonisten |
| MX2007002437A (es) * | 2004-09-01 | 2007-08-14 | Cv Therapeutics Inc | Metodo para el sanado de heridas utilizando antagonistas del receptor de adenosina a2b. |
| EP1799221A1 (en) | 2004-10-15 | 2007-06-27 | Cv Therapeutics, Inc. | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
| EP1891070A1 (en) | 2005-06-16 | 2008-02-27 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
| AU2007227021B2 (en) | 2006-03-17 | 2012-12-20 | Gilead Sciences, Inc. | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists |
| WO2008066627A2 (en) | 2006-10-24 | 2008-06-05 | Board Of Regents, The University Of Texas System | Adenosine signaling in diagnosis, treatment and prevention of priapism and erectile dysfunction |
| WO2009088518A1 (en) | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
| EP2268641B1 (en) * | 2008-03-26 | 2014-09-03 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
| WO2009157938A1 (en) | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| AU2011270701B2 (en) * | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| BR112012032766A2 (pt) | 2010-06-30 | 2019-09-24 | Gilead Sciences Inc | uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar |
| CN103261200B (zh) * | 2010-09-13 | 2016-03-30 | 阿迪维纳斯疗法有限公司 | 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途 |
| AR085942A1 (es) * | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
| WO2012170209A2 (en) * | 2011-05-23 | 2012-12-13 | Nectid, Inc. | Benzofuran-2 carboxamide compounds |
| US10117868B2 (en) | 2011-10-25 | 2018-11-06 | Case Western Reserve University | Systems pharmacology for treating ocular disorders |
| CN111093669A (zh) | 2017-08-14 | 2020-05-01 | 法斯瑞斯公司 | 用于治疗癌症的腺苷受体拮抗剂的微颗粒制剂 |
| CN111741752A (zh) | 2017-12-19 | 2020-10-02 | Gpcr治疗公司 | Gpcr异聚体抑制剂及其用途 |
| ES2975753T3 (es) | 2018-03-05 | 2024-07-12 | Teon Therapeutics Inc | Antagonistas del receptor de adenosina y usos de los mismos |
-
2019
- 2019-03-05 ES ES19764343T patent/ES2975753T3/es active Active
- 2019-03-05 IL IL277144A patent/IL277144B2/en unknown
- 2019-03-05 JP JP2020570407A patent/JP7849948B2/ja active Active
- 2019-03-05 AU AU2019232736A patent/AU2019232736B2/en active Active
- 2019-03-05 CN CN201980030563.6A patent/CN112218867B/zh active Active
- 2019-03-05 KR KR1020207028522A patent/KR102754522B1/ko active Active
- 2019-03-05 US US16/978,040 patent/US20210040097A1/en not_active Abandoned
- 2019-03-05 MX MX2020009286A patent/MX2020009286A/es unknown
- 2019-03-05 SG SG11202008611UA patent/SG11202008611UA/en unknown
- 2019-03-05 EP EP19764343.0A patent/EP3762386B1/en active Active
- 2019-03-05 WO PCT/US2019/020810 patent/WO2019173380A1/en not_active Ceased
- 2019-03-05 BR BR112020018158-7A patent/BR112020018158A2/pt unknown
- 2019-03-05 EP EP24152200.2A patent/EP4364727A3/en active Pending
-
2021
- 2021-02-02 US US17/165,736 patent/US11124515B2/en active Active
- 2021-08-02 US US17/391,245 patent/US20220056033A1/en not_active Abandoned
-
2024
- 2024-02-02 JP JP2024014959A patent/JP2024032976A/ja not_active Withdrawn
- 2024-06-28 AU AU2024204483A patent/AU2024204483B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019232736B2 (en) | 2024-05-02 |
| ES2975753T3 (es) | 2024-07-12 |
| US20210163483A1 (en) | 2021-06-03 |
| CN112218867B (zh) | 2023-11-21 |
| US20210040097A1 (en) | 2021-02-11 |
| AU2019232736A1 (en) | 2020-10-08 |
| IL277144B1 (en) | 2024-02-01 |
| JP7849948B2 (ja) | 2026-04-22 |
| JP2024032976A (ja) | 2024-03-12 |
| WO2019173380A1 (en) | 2019-09-12 |
| EP4364727A3 (en) | 2024-05-15 |
| AU2024204483B2 (en) | 2026-04-02 |
| EP3762386A1 (en) | 2021-01-13 |
| KR20200132901A (ko) | 2020-11-25 |
| IL277144B2 (en) | 2024-06-01 |
| US11124515B2 (en) | 2021-09-21 |
| EP3762386A4 (en) | 2021-11-24 |
| SG11202008611UA (en) | 2020-10-29 |
| CA3093234A1 (en) | 2019-09-12 |
| BR112020018158A2 (pt) | 2021-02-02 |
| JP2021517164A (ja) | 2021-07-15 |
| MX2020009286A (es) | 2020-12-11 |
| IL277144A (en) | 2020-10-29 |
| CN112218867A (zh) | 2021-01-12 |
| EP4364727A2 (en) | 2024-05-08 |
| AU2024204483A1 (en) | 2024-07-18 |
| US20220056033A1 (en) | 2022-02-24 |
| EP3762386B1 (en) | 2024-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102754522B1 (ko) | 아데노신 수용체 길항제 및 이의 용도 | |
| TWI856956B (zh) | 人類整合素α４β７拮抗劑 | |
| JP6602902B2 (ja) | 脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類 | |
| TWI473613B (zh) | 用作肥大細胞類胰蛋白酶抑制劑之〔４－（５－胺基甲基－２－氟－苯基）－六氫吡啶－１－基〕－〔７－氟－１－（２－甲氧基－乙基）－４－三氟甲氧基－１ｈ－吲哚－３－基〕－甲酮 | |
| WO2021000054A1 (en) | Cannabinoid derivatives | |
| JPS6338026B2 (https=) | ||
| CH679583A5 (https=) | ||
| HK40108164A (en) | Adenosine receptor antagonists and uses thereof | |
| JP2026074199A (ja) | アデノシン受容体アンタゴニストおよびその使用 | |
| HK40041747B (en) | Adenosine receptor antagonists and uses thereof | |
| HK40041747A (en) | Adenosine receptor antagonists and uses thereof | |
| CA3093234C (en) | Adenosine receptor antagonists and uses thereof | |
| EA043897B1 (ru) | Антагонисты аденозиновых рецепторов и их применения | |
| JP2021532069A (ja) | 新規な気管支拡張性ヘテロ結合アミド | |
| JP2730135B2 (ja) | 酸アミド誘導体 | |
| WO2016019847A1 (zh) | 一种氟代达比加群酯衍生物及其制备方法和在药学上的用途 | |
| JP5983714B2 (ja) | 含フッ素アミノ酸プロドラッグの結晶形とその製造方法 | |
| WO2025096782A1 (en) | Fluorinated cannabinoid compositions and methods thereof | |
| JPS642596B2 (https=) | ||
| JP2025518969A (ja) | イミダゾリジニルバニリン酸エーテル誘導体およびその使 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20201005 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220304 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240422 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241217 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250109 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250109 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |